BR9808424A - Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto. - Google Patents
Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto.Info
- Publication number
- BR9808424A BR9808424A BR9808424-0A BR9808424A BR9808424A BR 9808424 A BR9808424 A BR 9808424A BR 9808424 A BR9808424 A BR 9808424A BR 9808424 A BR9808424 A BR 9808424A
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- compound
- processes
- pharmaceutical composition
- intermediates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9706294.7A GB9706294D0 (en) | 1997-03-26 | 1997-03-26 | Heterocyclic compound |
| PCT/EP1998/001700 WO1998042673A1 (en) | 1997-03-26 | 1998-03-24 | Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9808424A true BR9808424A (pt) | 2000-05-23 |
Family
ID=10809909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9808424-0A BR9808424A (pt) | 1997-03-26 | 1998-03-24 | Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0971896A1 (zh) |
| JP (1) | JP2001518901A (zh) |
| KR (1) | KR20010005567A (zh) |
| CN (1) | CN1257482A (zh) |
| AP (1) | AP9901659A0 (zh) |
| AU (1) | AU731394B2 (zh) |
| BR (1) | BR9808424A (zh) |
| CA (1) | CA2284710A1 (zh) |
| EA (1) | EA199900755A1 (zh) |
| GB (1) | GB9706294D0 (zh) |
| HU (1) | HUP0001661A3 (zh) |
| ID (1) | ID24306A (zh) |
| IL (1) | IL131919A0 (zh) |
| IS (1) | IS5186A (zh) |
| NO (1) | NO994679L (zh) |
| NZ (1) | NZ337793A (zh) |
| PL (1) | PL335865A1 (zh) |
| TR (1) | TR199902315T2 (zh) |
| WO (1) | WO1998042673A1 (zh) |
| YU (1) | YU47699A (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9917822D0 (en) * | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
| DE10132725A1 (de) | 2001-07-05 | 2006-08-03 | Grünenthal GmbH | Substituierte γ-Lactonverbindungen |
| DE10137487A1 (de) * | 2001-08-03 | 2003-03-27 | Gruenenthal Gmbh | Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate |
| DE10306202A1 (de) * | 2003-02-13 | 2004-08-26 | Grünenthal GmbH | Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen |
| JP4360891B2 (ja) | 2003-12-09 | 2009-11-11 | アルパイン株式会社 | 放送受信機能を備えた電子装置およびその装置における電子番組ガイドの表示方法 |
| PT1908753E (pt) * | 2005-07-22 | 2015-02-06 | Mochida Pharm Co Ltd | Novo derivado acetamida de heterociclideno |
| RU2451014C2 (ru) * | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| JP7305560B2 (ja) | 2017-06-12 | 2023-07-10 | グリテック， エルエルシー | Ｎｍｄａアンタゴニスト及びｄ２／５ｈｔ２ａ又は選択的５ｈｔ２ａアンタゴニストによるうつ病の治療 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL93610A0 (en) * | 1989-03-08 | 1990-12-23 | Merck Sharp & Dohme | Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them |
| EA000875B1 (ru) * | 1995-09-29 | 2000-06-26 | ГЛАКСО ВЕЛЛКАМ С.п.А. | Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты) |
| GB9617305D0 (en) * | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
-
1997
- 1997-03-26 GB GBGB9706294.7A patent/GB9706294D0/en active Pending
-
1998
- 1998-03-24 AU AU72094/98A patent/AU731394B2/en not_active Ceased
- 1998-03-24 EP EP98919133A patent/EP0971896A1/en not_active Withdrawn
- 1998-03-24 AP APAP/P/1999/001659A patent/AP9901659A0/en unknown
- 1998-03-24 BR BR9808424-0A patent/BR9808424A/pt not_active IP Right Cessation
- 1998-03-24 YU YU47699A patent/YU47699A/sh unknown
- 1998-03-24 CA CA002284710A patent/CA2284710A1/en not_active Abandoned
- 1998-03-24 TR TR1999/02315T patent/TR199902315T2/xx unknown
- 1998-03-24 JP JP54323498A patent/JP2001518901A/ja active Pending
- 1998-03-24 HU HU0001661A patent/HUP0001661A3/hu unknown
- 1998-03-24 NZ NZ337793A patent/NZ337793A/en unknown
- 1998-03-24 ID IDW991108A patent/ID24306A/id unknown
- 1998-03-24 PL PL98335865A patent/PL335865A1/xx unknown
- 1998-03-24 KR KR1019997008630A patent/KR20010005567A/ko not_active Application Discontinuation
- 1998-03-24 EA EA199900755A patent/EA199900755A1/ru unknown
- 1998-03-24 IL IL13191998A patent/IL131919A0/xx unknown
- 1998-03-24 WO PCT/EP1998/001700 patent/WO1998042673A1/en not_active Application Discontinuation
- 1998-03-24 CN CN98805302A patent/CN1257482A/zh active Pending
-
1999
- 1999-09-17 IS IS5186A patent/IS5186A/is unknown
- 1999-09-24 NO NO994679A patent/NO994679L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU7209498A (en) | 1998-10-20 |
| EA199900755A1 (ru) | 2000-08-28 |
| IL131919A0 (en) | 2001-03-19 |
| IS5186A (is) | 1999-09-17 |
| GB9706294D0 (en) | 1997-05-14 |
| HUP0001661A3 (en) | 2001-12-28 |
| NO994679L (no) | 1999-11-24 |
| JP2001518901A (ja) | 2001-10-16 |
| KR20010005567A (ko) | 2001-01-15 |
| CA2284710A1 (en) | 1998-10-01 |
| ID24306A (id) | 2000-07-13 |
| TR199902315T2 (xx) | 2000-05-22 |
| YU47699A (sh) | 2001-12-26 |
| HUP0001661A2 (hu) | 2000-09-28 |
| CN1257482A (zh) | 2000-06-21 |
| WO1998042673A1 (en) | 1998-10-01 |
| PL335865A1 (en) | 2000-05-22 |
| EP0971896A1 (en) | 2000-01-19 |
| NZ337793A (en) | 2001-02-23 |
| NO994679D0 (no) | 1999-09-24 |
| AP9901659A0 (en) | 1999-09-30 |
| AU731394B2 (en) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9406363A (pt) | Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico | |
| ES2133785T3 (es) | Inhibidores de metaloproteinasas. | |
| BR9713489A (pt) | ácidos aminoalcanofosfÈnicos substituìdos | |
| DK0643726T3 (da) | Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei | |
| DE122011100032I1 (de) | Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer. | |
| BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| PT99445A (pt) | Processo para preparacao de derivados do 1,4,7,10-tetraazaciclododecano mono-n--substituidos e de composicoes farmaceuticas que os contem | |
| ATE61050T1 (de) | Pyridazinamine wirksam gegen viren. | |
| EE03969B1 (et) | (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid | |
| BR9709062A (pt) | Composto, composição farmacêutica, e, uso de um composto. | |
| PT98710A (pt) | Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem | |
| BR9714358A (pt) | Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos | |
| TR199802534T2 (xx) | Leptin (OB Protein) fragmanlar� | |
| BR0015416A (pt) | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos | |
| DE68913762D1 (de) | Diarylverbindungen als antiatherosklerotische Mittel. | |
| BR9910329A (pt) | Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto | |
| FI972308A0 (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
| DE3853910D1 (de) | Molekulare köder und deren verwendung. | |
| ATE83376T1 (de) | Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten. | |
| BR9808424A (pt) | Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto. | |
| ATE204177T1 (de) | Verwendung von substanz p antagonist im pharmazeutischer zusammensetzung | |
| NO941681D0 (no) | Humane IL-4 mutant proteiner | |
| BR9813514A (pt) | Agente para tratamento de fibras queratìnicas | |
| BR9809234A (pt) | Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo. | |
| SE9402880D0 (sv) | New peptide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A,7A,8A E 9A |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1892 DE 10/04/2007. |